

**DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE  
(JAPC)**



**Quick Reference Guide- Ongoing monitoring requirements for Drugs affecting the Immune Response**

See individual SCG for baseline monitoring requirements. Standard GP monitoring schedule following at least 6 weeks of dose stability as below

	<b>FBC, ALT and/or AST &amp; albumin Creatinine/ calculated GFR/ U&amp;E</b>	<b>Other</b>	<b>BP</b>	<b>Urinalysis</b>	<b>Additional comments</b>
<b>Azathioprine / 6 mercaptopurine</b>	Monthly for 3 month Three-monthly thereafter				
<b>Ciclosporin</b>	Monthly	Glucose- HbA1c 3 monthly	Monthly		Patients who have been stable for 12 months can be considered for reduced frequency of monitoring on an individual patient basis. Monthly monitoring has been locally agreed. Longer interval monitoring is by exception liaising directly with consultant
<b>Leflunomide</b>	Monthly for 3 month Three-monthly thereafter	Ask patient to report any unexplained weight loss (>10%)	Monthly for 3 month Three-monthly thereafter		Leflunomide in combination with MTX requires extended monthly monitoring for at least 12 months. Patients who have been stable for 12 months can be considered for reduced frequency of monitoring on an individual patient basis.
<b>Methotrexate (oral and parenteral)</b>	Monthly for 3 month Three-monthly thereafter				
<b>Penicillamine</b>	Monthly	Ask patient about presence of rash or oral ulceration at each visit; CRP/ESR every 3months		Monthly	Patients who have been stable for 12 months can be considered for reduced frequency of monitoring (every 3 months) on an individual patient basis.
<b>Sulfasalazine (Sulphasalazine)</b>	Monthly for 3 month Three-monthly thereafter Increase interval to 6-monthly if monitoring stable for 12 months.				

For complete shared care agreements see [http://www.derbyshiremedicinesmanagement.nhs.uk/medicines-management/clinical-guidelines/shared\\_care\\_guidelines](http://www.derbyshiremedicinesmanagement.nhs.uk/medicines-management/clinical-guidelines/shared_care_guidelines)